174 related articles for article (PubMed ID: 31515941)
1. The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma.
Hashwah H; Bertram K; Stirm K; Stelling A; Wu CT; Kasser S; Manz MG; Theocharides AP; Tzankov A; Müller A
EMBO Mol Med; 2019 Oct; 11(10):e10576. PubMed ID: 31515941
[TBL] [Abstract][Full Text] [Related]
2. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.
Stirm K; Leary P; Bertram K; Núñez NG; Wüst D; Boudesco C; Verhoeyen E; Zenz T; Becher B; Menter T; Tzankov A; Müller A
Oncoimmunology; 2021; 10(1):2003533. PubMed ID: 34858727
[TBL] [Abstract][Full Text] [Related]
4. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma.
Stelling A; Hashwah H; Bertram K; Manz MG; Tzankov A; Müller A
Blood; 2018 May; 131(20):2235-2246. PubMed ID: 29615404
[TBL] [Abstract][Full Text] [Related]
6. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
7. Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas.
Sarosiek KA; Malumbres R; Nechushtan H; Gentles AJ; Avisar E; Lossos IS
Blood; 2010 Jan; 115(3):570-80. PubMed ID: 19965678
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
10. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
12. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
[TBL] [Abstract][Full Text] [Related]
15. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
16. RTK signaling requires C3ar1/C5ar1 and IL-6R joint signaling to repress dominant PTEN, SOCS1/3 and PHLPP restraint.
Strainic MG; Pohlmann E; Valley CC; Sammeta A; Hussain W; Lidke DS; Medof ME
FASEB J; 2020 Feb; 34(2):2105-2125. PubMed ID: 31908021
[TBL] [Abstract][Full Text] [Related]
17. Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels.
Zhong W; Zhu Z; Xu X; Zhang H; Xiong H; Li Q; Wei Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):73. PubMed ID: 30755239
[TBL] [Abstract][Full Text] [Related]
18. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.
Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J
Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
